Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial
暂无分享,去创建一个
Amy Shui | Nader Rifai | Robert M Califf | David A Morrow | R. Califf | M. Sabatine | E. Braunwald | N. Rifai | D. Morrow | J. D. de Lemos | S. Wiviott | A. Shui | James A de Lemos | Marc S Sabatine | Eugene Braunwald | Stephen D Wiviott | Michael A Blazing | M. Blazing
[1] P. Ridker. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. , 2003, Circulation.
[2] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[3] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[4] C. Cannon,et al. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. , 2005, Journal of the American College of Cardiology.
[5] D. Morrow,et al. Is C-reactive protein an innocent bystander or proatherogenic culprit?: The Verdict Is Still Out , 2006, Circulation.
[6] P. Ridker,et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. , 2005, Journal of the American College of Cardiology.
[7] François Mach,et al. Inflammation and Atherosclerosis , 2004, Herz.
[8] P. Libby,et al. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets , 2002, Nature Medicine.
[9] Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.
[10] J. Torzewski. C-reactive protein and atherogenesis: new insights from established animal models. , 2005, The American journal of pathology.
[11] P. Ridker,et al. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. , 1999, The American journal of cardiology.
[12] Sidney C. Smith,et al. MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .
[13] Gary L Myers,et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.
[14] R. Califf,et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. , 2005, JAMA.
[15] P. Libby,et al. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets , 2003, Nature Network Boston.
[16] James T. Willerson,et al. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.
[17] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[18] L. Wallentin,et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. , 2004, Clinical chemistry.
[19] Paul Schoenhagen,et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.
[20] N Rifai,et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. , 2001, Clinical chemistry.
[21] P. Libby,et al. High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study , 2003, Circulation.
[22] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[23] R. Califf,et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. , 2001, American heart journal.
[24] Nader Rifai,et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.
[25] R. Karas,et al. Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease , 2003, Annals of Internal Medicine.
[26] E. Poehlman,et al. Weight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women , 2002, Circulation.
[27] David A Morrow,et al. Future of Biomarkers in Acute Coronary Syndromes Moving Toward a Multimarker Strategy , 2003, Circulation.
[28] S. Grundy,et al. Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.